Jeffrey L. Cleland
Chief Executive Officer at Ashvattha Therapeutics Inc
Profile
Jeffrey L.
Cleland was the founder of Targesome, Inc. (founded in 2002) where he served as Vice President-Research & Development from 2002 to 2003.
He is also the founder of Versartis, Inc. (founded in 2008) where he held the titles of President, Chief Executive Officer & Director from 2014 to 2015.
Additionally, he founded Diartis Pharmaceuticals, Inc. (founded in 2010) and served as Chief Executive Officer in 2011.
Currently, Dr. Cleland is the Executive Chairman of Orpheris, Inc. (founded in 2015).
In his current roles, Dr. Cleland is the Executive Chairman, President & CEO of Ashvattha Therapeutics Inc. He is also a Director at Exicure Operating Co., Elixirgen Therapeutics, Inc., ImmunSYS, Inc., Syncromune, Inc., and a Member of the American Chemical Society, American Institute of Chemical Engineers, and The Controlled Release Society.
Previously, Dr. Cleland served as President, Chief Executive Officer & Director of Graybug Vision, Inc. from 2014 to 2018.
He was also the President & Chief Executive Officer of Ilypsa, Inc. and an Independent Director at Exicure, Inc. from 2019 to 2023.
He held the position of Senior Scientist at Genentech, Inc. and Vice President-Therapeutic Development at BaroFold, Inc. from 2007 to 2009.
Additionally, he was Vice President-Technical Operations at Novacea, Inc. and a Member of the American Association for the Advancement of Science.
Dr. Cleland holds a doctorate degree from the Massachusetts Institute of Technology and an undergraduate degree from the University of California, Davis.
Jeffrey L. Cleland active positions
| Companies | Position | Start |
|---|---|---|
The Controlled Release Society
 The Controlled Release Society Miscellaneous Commercial ServicesCommercial Services The Controlled Release Society is a private company that focuses on providing fundamental delivery research, development, regulatory science, and clinical translation. The company is based in St. Paul, MN. The company was founded by Agis Kydonieus. | Corporate Officer/Principal | - |
American Chemical Society
 American Chemical Society Miscellaneous Commercial ServicesCommercial Services American Chemical Society engages as a scientific society which supports scientific inquiry in the field of chemistry. The company was founded in 1876 and is headquartered in Washington, DC. | Corporate Officer/Principal | - |
American Institute of Chemical Engineers
 American Institute of Chemical Engineers Miscellaneous Commercial ServicesCommercial Services The American Institute of Chemical Engineers (AIChE) is a professional society with over 60,000 members in more than 110 countries. The private company is based in New York, NY, and has subsidiaries in the United States. AIChE offers various programs, including e-learning, webinars, and career advancement, to help chemical engineers at every career juncture bridge the skills gap created by the rush of technology, changing work styles, and unprecedented societal needs. Founded in 1908, AIChE is a focal point for information exchange on the frontiers of chemical engineering research in areas such as energy, sustainability, biological and environmental engineering, nanotechnology, and chemical plant safety and security. | Corporate Officer/Principal | - |
Ashvattha Therapeutics Inc
 Ashvattha Therapeutics Inc Pharmaceuticals: MajorHealth Technology Ashvattha Therapeutics LLC provides healthcare services. The firm develops pharmaceutical products. The company is headquartered in Redwood City, CA. | Chief Executive Officer | - |
Orpheris, Inc.
 Orpheris, Inc. BiotechnologyHealth Technology Orpheris, Inc. provides healthcare services. The firm focused on the treatment of neuroinflammatory orphan diseases. The company was founded was founded in 2015 and is headquartered in Redwood City, CA. | Founder | 2014-12-31 |
ImmunSYS, Inc.
 ImmunSYS, Inc. Pharmaceuticals: MajorHealth Technology ImmunSYS, Inc. is a clinical stage biopharmaceutical company focused on the development of cancer immunotherapy products. The company was founded by Eamonn P. Hobbs and Charles J. Link Jr. in March 2018 and is headquartered in Fort Lauderdale, FL. | Director/Board Member | - |
Exicure Operating Co.
 Exicure Operating Co. Pharmaceuticals: MajorHealth Technology Exicure Operating Co. operates as a biopharmaceutical company commercializing spherical nucleic acid constructs as gene regulation and modulation agents for diseases including applications in oncology, dermatology, neurology, and for immune disorders. The SNA constructs allow the use of oligonucleotide-based therapies to treat diseases in a range of tissue types. The company was founded by Chad A. Mirkin and Colby Shad Thaxton in 2011 and is headquartered in Skokie, IL. | Director/Board Member | 2019-06-30 |
Syncromune, Inc.
 Syncromune, Inc. Pharmaceuticals: MajorHealth Technology Syncromune, Inc. is a clinical-stage biopharmaceutical company that is dedicated to developing an in situ platform technology optimized for metastatic solid tumor cancers. The company is based in Fort Lauderdale, FL. The company is currently developing Sync-T™, a novel combination drug/device treatment platform that aims to achieve high response rates with potentially curative efficacy. The therapy is designed to synchronize in situ neoantigen T cell education and immunostimulation via intratumoral/locoregional infusion, with the goal of enabling the immune system to recognize and attack cancer throughout the body. The first two candidates, SV-101 and SV-102, are currently in investigator-initiated phase 1 trials. Link. The company was founded in 2020 by Charles J. Eamonn P. Hobbs has been the CEO of the company since 2020. | Director/Board Member | - |
Elixirgen Therapeutics, Inc.
 Elixirgen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Elixirgen Therapeutics, Inc. operates as a biotechnology company. It develops and sells stem cell therapies for genetic diseases. The company was founded by Akihiro Ko and Minoru S. H. Ko in 2017 and is headquartered in Baltimore, MD. | Director/Board Member | 2022-12-20 |
Former positions of Jeffrey L. Cleland
| Companies | Position | End |
|---|---|---|
| ░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░░ ░░░░ | ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░ | - |
| ░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Training of Jeffrey L. Cleland
| Massachusetts Institute of Technology | Doctorate Degree |
| University of California, Davis | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| EXICURE, INC. | Health Technology |
| Private companies | 18 |
|---|---|
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
BaroFold, Inc.
 BaroFold, Inc. Pharmaceuticals: MajorHealth Technology BaroFold, Inc. develops and commercializes protein therapeutics. Its services include protein refolding, protein analytical and aggregate characterization, formulation stability and immunogenicity studies, and microbial expression. The company was founded by Matthew Seefeldt, Matthew Brewer, John F. Carpenter, Ted Randolph, Timothy C. Rodell, and Lyndal K. Hesterberg in 2009 and is headquartered in Aurora, CO. | Health Technology |
Graybug Vision, Inc.
 Graybug Vision, Inc. Pharmaceuticals: MajorHealth Technology Graybug Vision, Inc. develops ophthalmic drugs. It focus on developing drug delivery therapies for the treatment of eye diseases such as age-related macular degeneration and glaucoma. The company was founded by Justin S. Hanes, Peter John McDonnell, Christy Wyskiel and Peter A. Campochiaro in May 2011 and is headquartered in Redwood City, CA. | Health Technology |
American Chemical Society
American Chemical Society Miscellaneous Commercial ServicesCommercial Services American Chemical Society engages as a scientific society which supports scientific inquiry in the field of chemistry. The company was founded in 1876 and is headquartered in Washington, DC. | Commercial Services |
Novacea, Inc.
 Novacea, Inc. Pharmaceuticals: MajorHealth Technology Novacea, Inc. is a privately held biopharmaceutical company focused on licensing, developing and commercializing novel agents to revolutionize the treatment of cancer. Novacea’s in-licensed product portfolio features three clinical stage oncology therapeutics. The Company has two products which are anticipated to commence Phase 3 clinical trials in 2006, DN-101 and vinorelbine oral. Banoxantrone (AQ4N) is in Phase 1/2 clinical trials. It is located in South San Francisco, CA. | Health Technology |
Ilypsa, Inc.
 Ilypsa, Inc. BiotechnologyHealth Technology Ilypsa, Inc. operates a biopharmaceutical firm. It develops renal care pharmaceutical products. The company was founded on March 6, 2003 and is headquartered in Thousand Oaks, CA. | Health Technology |
American Association for the Advancement of Science
 American Association for the Advancement of Science Miscellaneous Commercial ServicesCommercial Services The American Association for the Advancement of Science provides science related journal, program, and education services. The firm also promotes the responsible use of science in public policy. The company was founded in 1848 and is headquartered in Washington, DC. | Commercial Services |
American Institute of Chemical Engineers
American Institute of Chemical Engineers Miscellaneous Commercial ServicesCommercial Services The American Institute of Chemical Engineers (AIChE) is a professional society with over 60,000 members in more than 110 countries. The private company is based in New York, NY, and has subsidiaries in the United States. AIChE offers various programs, including e-learning, webinars, and career advancement, to help chemical engineers at every career juncture bridge the skills gap created by the rush of technology, changing work styles, and unprecedented societal needs. Founded in 1908, AIChE is a focal point for information exchange on the frontiers of chemical engineering research in areas such as energy, sustainability, biological and environmental engineering, nanotechnology, and chemical plant safety and security. | Commercial Services |
The Controlled Release Society
The Controlled Release Society Miscellaneous Commercial ServicesCommercial Services The Controlled Release Society is a private company that focuses on providing fundamental delivery research, development, regulatory science, and clinical translation. The company is based in St. Paul, MN. The company was founded by Agis Kydonieus. | Commercial Services |
| Targesome, Inc. | Health Services |
Versartis, Inc.
 Versartis, Inc. Pharmaceuticals: MajorHealth Technology Versartis, Inc. is an endocrine-focused biopharmaceutical company, which engages in the research and development of pharmaceutical products. Its portfolio includes Somavartan and XTEN TEchnology which target the endocrine disorders and growth hormone deficiencies. The company was founded by Jeffrey L. Cleland, Mark de Boer, Willem Stemmer, Volker Schellenberger, and Joshua Silverman on December 10, 2008 and is headquartered in Menlo Park, CA. | Health Technology |
Diartis Pharmaceuticals, Inc.
 Diartis Pharmaceuticals, Inc. BiotechnologyHealth Technology Diartis Pharmaceuticals, Inc. developed therapeutic proteins for the treatment of metabolic disorders. The company was founded by Jeffrey L. Clearland in December 2010 and headquartered in Redwood City, CA. | Health Technology |
Exicure Operating Co.
Exicure Operating Co. Pharmaceuticals: MajorHealth Technology Exicure Operating Co. operates as a biopharmaceutical company commercializing spherical nucleic acid constructs as gene regulation and modulation agents for diseases including applications in oncology, dermatology, neurology, and for immune disorders. The SNA constructs allow the use of oligonucleotide-based therapies to treat diseases in a range of tissue types. The company was founded by Chad A. Mirkin and Colby Shad Thaxton in 2011 and is headquartered in Skokie, IL. | Health Technology |
Ashvattha Therapeutics Inc
Ashvattha Therapeutics Inc Pharmaceuticals: MajorHealth Technology Ashvattha Therapeutics LLC provides healthcare services. The firm develops pharmaceutical products. The company is headquartered in Redwood City, CA. | Health Technology |
Orpheris, Inc.
Orpheris, Inc. BiotechnologyHealth Technology Orpheris, Inc. provides healthcare services. The firm focused on the treatment of neuroinflammatory orphan diseases. The company was founded was founded in 2015 and is headquartered in Redwood City, CA. | Health Technology |
Elixirgen Therapeutics, Inc.
Elixirgen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Elixirgen Therapeutics, Inc. operates as a biotechnology company. It develops and sells stem cell therapies for genetic diseases. The company was founded by Akihiro Ko and Minoru S. H. Ko in 2017 and is headquartered in Baltimore, MD. | Health Technology |
ImmunSYS, Inc.
ImmunSYS, Inc. Pharmaceuticals: MajorHealth Technology ImmunSYS, Inc. is a clinical stage biopharmaceutical company focused on the development of cancer immunotherapy products. The company was founded by Eamonn P. Hobbs and Charles J. Link Jr. in March 2018 and is headquartered in Fort Lauderdale, FL. | Health Technology |
Syncromune, Inc.
Syncromune, Inc. Pharmaceuticals: MajorHealth Technology Syncromune, Inc. is a clinical-stage biopharmaceutical company that is dedicated to developing an in situ platform technology optimized for metastatic solid tumor cancers. The company is based in Fort Lauderdale, FL. The company is currently developing Sync-T™, a novel combination drug/device treatment platform that aims to achieve high response rates with potentially curative efficacy. The therapy is designed to synchronize in situ neoantigen T cell education and immunostimulation via intratumoral/locoregional infusion, with the goal of enabling the immune system to recognize and attack cancer throughout the body. The first two candidates, SV-101 and SV-102, are currently in investigator-initiated phase 1 trials. Link. The company was founded in 2020 by Charles J. Eamonn P. Hobbs has been the CEO of the company since 2020. | Health Technology |
- Stock Market
- Insiders
- Jeffrey L. Cleland
